Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoune M, Cauquil C, Martin-Romano P, Baldini C, Laparra A, Vuagnat P, Hollebecque A, Mateus C, Besse B, Naltet C, Robert C, Marabelle A, Massard C, Lambotte O, Michot JM. Hajem S, et al. Among authors: laparra a. Eur J Cancer. 2021 Nov;157:383-390. doi: 10.1016/j.ejca.2021.08.045. Epub 2021 Sep 24. Eur J Cancer. 2021. PMID: 34571335
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O. Simonaggio A, et al. Among authors: laparra a. JAMA Oncol. 2019 Sep 1;5(9):1310-1317. doi: 10.1001/jamaoncol.2019.1022. JAMA Oncol. 2019. PMID: 31169866 Free PMC article.
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
Laparra A, Kfoury M, Champiat S, Danlos FX, Martin-Romano P, Simonaggio A, Baldini C, Vuagnat P, Mateus C, Voisin AL, Albiges L, Besse B, Even C, Robert C, Laghouati S, Massard C, Marabelle A, Lambotte O, Michot JM. Laparra A, et al. Ann Oncol. 2021 Jul;32(7):936-937. doi: 10.1016/j.annonc.2021.04.006. Epub 2021 Apr 15. Ann Oncol. 2021. PMID: 33865965 Free article. No abstract available.
Neuropathies périphériques associées aux syndromes lymphoprolifératifs : spectre clinique et démarche diagnostique.
Pacoureau L, Labeyrie C, Catalan P, Echaniz-Laguna A, Henriquez S, Laparra A, Cauquil C, Chrétien P, Hacein-Bey-Abina S, Goujard C, Adam C, Lambotte O, Adams D, Noël N. Pacoureau L, et al. Among authors: laparra a. Rev Med Interne. 2021 Dec;42(12):844-854. doi: 10.1016/j.revmed.2021.06.013. Epub 2021 Aug 7. Rev Med Interne. 2021. PMID: 34373143 French.
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
Cabanié C, Ammari S, Hans S, Pobel C, Laparra A, Danlos FX, Chanson N, Dolidon S, Seban R, Voisin AL, Pautier P, Romano-Martin P, Even C, Baldini C, Besse B, Albiges L, Boutros C, Routier E, Balleyguier C, De Montpreville VT, Champiat S, Massard C, Robert C, Marabelle A, Mateus C, Lambotte O, Le Pavec J, Michot JM. Cabanié C, et al. Among authors: laparra a. Eur J Cancer. 2021 Oct;156:46-59. doi: 10.1016/j.ejca.2021.07.015. Epub 2021 Aug 20. Eur J Cancer. 2021. PMID: 34425404
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM. Ruste V, et al. Among authors: laparra a. Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7. Eur J Cancer. 2021. PMID: 34627664
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae.
Plaçais L, Michot JM, Champiat S, Romano-Martin P, Baldini C, Joao MS, Marabelle A, Voisin AL, Not A, Labeyrie C, Beaudonnet G, Laparra A, Maria ATJ, Masseau A, Dehette S, Deleporte A, Echaniz-Laguna A, Denier C, Adams D, Lambotte O, Noel N, Cauquil C. Plaçais L, et al. Among authors: laparra a. Brain Commun. 2021 Oct 1;3(4):fcab220. doi: 10.1093/braincomms/fcab220. eCollection 2021. Brain Commun. 2021. PMID: 34651126 Free PMC article.
28 results